VCAM1 and multiple sclerosis: Indeed, α1ACT was recently identified as a potential biomarker for progressive for multiple sclerosis due to its elevated levels in cerebrospinal fluid95, which could be connected to increased VCAM-1 expression at the BBB to license immune cell entry into the brain.